MILWAUKEE, Oct. 22, 2021 /PRNewswire-PRWeb/ -- The
Society for Immunotherapy of Cancer (SITC) is pleased to announce
BioNTech cofounders Uğur Şahin, MD and Özlem Türeci, MD as the
recipients of the SITC Medal of Honor for the development of the
vaccine against COVID-19.
Dr. Şahin and Dr. Türeci, whose efforts championing the
development and distribution of the vaccine against COVID-19 using
mRNA technology saved countless lives, will be honored in-person
during the society's 36th Annual Meeting on Sunday, Nov. 14, 2021 at the Walter E. Washington
Convention Center in Washington,
D.C. Dr. Şahin and Dr. Türeci will share the story of
Project Lightspeed and the development of the COVID-19 vaccine.
"We are grateful to Dr. Şahin and Dr. Türeci," said SITC
President Patrick Hwu, MD. "We all
recognize the incredible contributions of Project Lightspeed to
humanity, and we are honored to have them accept this medal and
present at SITC 2021."
Following the presentation of the Medal of Honor and
presentation on Project Lightspeed, Dr. Şahin will lead a
scientific hot topic session, RNA Vaccines: from COVID back to
Cancer, with Tal Zaks, MD, PhD. Dr.
Şahin and Dr. Zaks will discuss the future of RNA vaccines for
cancer and what the cancer immunotherapy community can learn from
the COVID-19 vaccine.
To learn more about this award, visit SITC CONNECT.
The Society for Immunotherapy of Cancer (SITC) is the world's
leading member-driven organization specifically dedicated to
improving cancer patient outcomes by advancing the science and
application of cancer immunotherapy. Established in 1984, SITC, a
501(c)(3) not-for-profit organization, serves scientists,
clinicians, academicians, patients, patient advocates, government
representatives and industry leaders from around the world. Through
educational programs that foster scientific exchange and
collaboration, SITC aims to one day make the word cure a reality
for cancer patients everywhere. To learn more, visit
http://www.sitcancer.org and follow us on Twitter, LinkedIn,
Facebook and YouTube.
Thomas Martin, Society for
Immunotherapy of Cancer, 414 271 2456, firstname.lastname@example.org
SOURCE Society for Immunotherapy of Cancer